Skip to content
Medical Health Aged Care

Ramsay Health Care makes landmark Australian investment in robotic surgical technology

Ramsay Health Care 2 mins read

Ramsay Health Care has made one of Australia’s largest single purchases of robotic surgical systems, with 12 new Stryker Mako robots set to be delivered to hospitals across the country over the next three months. The investment strengthens Ramsay’s commitment to modern, innovative health care options that support excellent patient outcomes.

Ramsay Health Care’s Chief Operating Officer, Stuart Winters, said Ramsay has a long history of investing in innovation that delivers clear value for patients, clinicians and the broader system.

“This investment means more patients, in more communities, will benefit from world-class surgical technology designed to support more personalised care, improved accuracy, and faster recovery times,” Mr Winters said.

As well as providing measurable benefits for patients, Mr Winters said the strategic investment has the potential to strengthen the sustainability of Australian health care.

“Robotic-assisted surgery allows our surgeons and clinical teams the potential to modernise the way joint replacement surgery is delivered and create enduring value for the communities we serve.

“Robotic systems like Mako support surgeons to work with greater accuracy and consistency, which can reduce complications, shorten lengths of stay and create capacity across our theatres and wards.

“As our population continues to age and demand for joint replacement continues to grow*, we’re making sure our hospitals, clinicians and systems are ready.”

The Stryker Mako system is widely recognised as one of the most advanced robotic-assisted platforms for hip and knee replacement surgery, with the devices also soon to be used in shoulder procedures.

12 new robots will be installed at Ramsay Health Care hospitals across New South Wales, Queensland, Western Australia and Victoria.

“Ramsay’s scale allows us to invest in technology that lifts performance across the entire network,” Mr Winters said.

“The introduction of the additional Mako robots strengthens Ramsay’s national robotic surgery program, which already supports thousands of joint replacement procedures each year.”

Ramsay’s investment in robotic technology sits alongside broader work to modernise models of care, digital pathways, clinical training, and sustainability initiatives across its Australian network.

“People caring for people is at the heart of our work,” Mr Winters said.

“When we invest in innovation, we’re investing in our clinicians, our communities and the future of health care.”

*National Library of Medicine: Actual versus Forecast Burden of Primary Hip and Knee Replacement Surgery in Australia: Analysis of Data from the Australian Orthopaedic Association National Joint Replacement Registry

Media contact:
Kirsty Clinton Media and External Relations Manager, Ramsay Health Care
Email: [email protected] | Mobile: 0455 882 474

Media

More from this category

  • Medical Health Aged Care
  • 26/02/2026
  • 23:11
Kairos Pharma, Ltd

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. LOS ANGELES--BUSINESS WIRE--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer…

  • Medical Health Aged Care
  • 26/02/2026
  • 22:12
BeOne Medicines Ltd.

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year…

  • Contains:
  • Government Federal, Medical Health Aged Care
  • 26/02/2026
  • 16:34
Australian Primary Health Care Nurses Association (APNA)

MEDIA RELEASE: APNA welcomes Senate Committee recommendation?

The Australian Primary Health Care Nurses Association (APNA) warmly welcomes the recommendation of the Senate Community Affairs Committee that theSenatepass the Health Legislation Amendment (Prescribing of Pharmaceutical Benefits) Bill 2025.  TheSenate Committee reportis a significant step in the journey towards allowing authorised registered nurse prescribers to prescribe under the Pharmaceutical Benefits Scheme (PBS).  APNA President Denise Lyons said the recommendation is a win for patients, communities, and the health system, and reflects a clear recognition of the vital role nurses play in delivering timely, safe and accessible healthcare.  “This is an important stepfor Australia’s primary health care system,” Denise said.  "Allowing highly experienced, skilled and trusted nurses…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.